ARTES adds SplitCore technology to vaccine development portfolio


ARTES adds SplitCore technology to vaccine development portfolio


Artes Logo 150 x 74

Press Release | ARTES Biotechnology GmbH

JANUARY 07, 2019

Langenfeld, Germany: – ARTES Biotechnology, the German-based recombinant protein and vaccines specialist CRO, has announced acquisition of the unique SplitCore technology developed at Germany’s University of Freiburg.

The SplitCore technology is based on flexible integration and presentation of foreign antigens on the surface of capsid virus like particles (cVLPs) produced in bacteria and yeast.

Building on METAVAX® platform

With its yeast based METAVAX® platform for antigen presentation on envelope virus like particles (eVLPs), ARTES is already well established and a preferred partner for human and animal vaccine development projects. The inclusion of the SplitCore technology in ARTES’ vaccine development portfolio enables the company to offer customers an even broader spectrum of services to develop specific vaccines.

“With the two potent and versatile platforms, SplitCore and METAVAX®, we can now offer the full range of nanoparticle based vaccine development, covering both capsid VLPs and envelope VLPs,” commented ARTES Director of Technology, Volker Jenzelewski.

Recombinant production compatibility

“Antigens, ranging from peptide epitopes to complex proteins, are compatible with these technologies and can be manufactured in all major recombinant production platforms including E. coli, yeast and CHO cells”, said Mr. Jenzelewski.

“SplitCore will substantially complement our capability to address technical and economic challenges our pharmaceutical customers may face. Together with our METAVAX® platform, which already result in several vaccine candidates manufactured, we are now even stronger positioned to support the development of innovative vaccines,” he added.

Split core antigens

SplitCore is based on a technology that can split the core or capsid protein of Hepatitis B virus into two parts. These split core antigens form efficiently nanoparticles known as capsid virus like particles (cVLPs).

SplitCore enables differently structured proteins to be added onto the surface of those particles, with a high degree of freedom. These enhanced particles can then be presented highly exposed to the immune system and hence more effective.

About ARTES Biotechnology

ARTES Biotechnology is a pharmaceutical contract research & development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms.

ARTES specializes in recombinant protein production, process and vaccine development from microbial expression systems, marketing the unique METAVAX® (dHepB-eVLP) and SplitCore (HepB-cVLP) technology in combination with yeast expression.

ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.

Media Contact

Dr.Melanie Piontek, Business Development Director, ARTES Biotechnology GmbH
Tel: +49 (0)217 327 587 12
Email: piontek@artes-biotechnology.com

Resources

Click on ARTES acquires SplitCore technology for more information.
Click on ARTES to contact the company directly.


Supplier Information
Supplier: ARTES Biotechnology GmbH
Address: Elisabeth-Selbert-Str. 9, 40764 Langenfeld, Germany
Tel: +49 (0) 2173 27587-0
Fax: +49 (0) 2173 27587-77
Website: www.artes-biotechnology.com


Comments are closed.